Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén
Bo
B
Department of Clinical Sciences, Division of Medicine, Lund University, Lund, Sweden. bo.ahren@med.lu.se
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D058892:Adenosine Deaminase Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines; D011759:Pyrrolidines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles; D000077597:Vildagliptin
D058892:Adenosine Deaminase Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D009570:Nitriles; D011480:Protease Inhibitors; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate